MAZE on Nasdaq
Maze Therapeutics, Inc.
In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly-owned clinical programs, MZE829 and MZE782.”4 It is headquartered in South San Francisco, California.1 Its shares trade on Nasdaq under the symbol MAZE.1
Price unavailable
Last updated Oct 21, 2026.
Overview
-$131.1MNet income, fiscal 20252
Compare with REGENXBIO Inc., Adaptimmune (United Kingdom) or Aerie Pharmaceuticals, or pick any stock.
- TickerMAZE on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersSouth San Francisco, California1
- Incorporated inDE3
- Business address171 Oyster Point Boulevard, Suite 300, South San Francisco, Ca 940803
- Filer category, Emerging growth company3
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly-owned clinical programs, MZE829 and MZE782.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development50¢$83.5M
- Other costs18¢$30.6M
- Income tax1¢$1.2M
- Profit31¢$52.2M
Out of $167.5M in revenue.2
Where each dollar of operating cash went, fiscal 2024
- Capital spending2¢$1.1M
- Kept or used elsewhere98¢$74.8M
Out of $76.0M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| License revenue | $167.5M | |
| Research and development | $108.4M | $83.5M |
| General and administrative | $34.5M | $26.4M |
| Total operating expenses | $142.9M | $109.9M |
| (Loss) income from operations | -$142.9M | $57.6M |
| Interest and other income, net | $11.8M | $4.7M |
| Change in fair value of convertible promissory notes | $0 | -$8.8M |
| (Loss) income before income tax expense | -$131.1M | $53.4M |
| Income tax expense | $0 | -$1.2M |
| Net (loss) income | -$131.1M | $52.2M |
| Net (loss) income attributable to common stockholders, basic (see Note 14) | -$131.1M | $3.4M |
| Net (loss) income attributable to common stockholders, diluted (see Note 14) | -$131.1M | $3.4M |
| Basic | -$3.05 | $1.42 |
| Diluted | -$3.05 | $1.25 |
| Basic | 43.0M shares | 2.4M shares |
| Diluted | 43.0M shares | 2.7M shares |
| Net unrealized gain on marketable securities | $110.0K | |
| Comprehensive (loss) income | -$131.0M | $52.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $189.2M | $196.8M | |
| Marketable securities, current | $152.7M | ||
| Prepaid expenses and other current assets | $7.8M | $4.9M | |
| Total current assets | $349.7M | $201.7M | |
| Property and equipment, net | $5.0M | $6.7M | |
| Restricted cash | $1.1M | $1.1M | |
| Marketable securities, non-current | $18.1M | ||
| Operating lease right-of-use asset | $20.1M | $23.2M | |
| Other assets | $3.0M | $7.9M | |
| Total assets | $397.1M | $240.5M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued expenses and other current liabilities | $16.0M | $14.1M | |
| Operating lease liabilities, current | $4.8M | $4.6M | |
| Total current liabilities | $22.6M | $20.7M | |
| Operating lease liabilities, net of current portion | $18.5M | $22.0M | |
| Other liabilities, non-current | $1.1M | $969.0K | |
| Total liabilities | $42.2M | $43.6M | |
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of December 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | $0 | $508.1M | |
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 49,335,551 and 2,446,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively; 10,372 shares subject to repurchase as of December 31, 2025 and 2024 | $49.0K | $2.0K | |
| Additional paid-in-capital | $844.4M | $47.2M | |
| Accumulated other comprehensive income | $110.0K | ||
| Accumulated deficit | -$489.5M | -$358.4M | |
| Total stockholders' equity (deficit) | $355.0M | -$311.2M | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $397.1M | $240.5M | |
| Preferred stock, par or stated value per share | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | 410.0M shares |
| Common stock, shares, issued | 49.3M shares | 2.4M shares | |
| Common stock, shares, outstanding | 49.3M shares | 2.4M shares | |
| Common stock, shares, subject to repurchase | 10.4K shares | 10.4K shares |
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $189.2M | $196.8M | |
| Marketable securities, current | $152.7M | ||
| Prepaid expenses and other current assets | $7.8M | $4.9M | |
| Total current assets | $349.7M | $201.7M | |
| Property and equipment, net | $5.0M | $6.7M | |
| Restricted cash | $1.1M | $1.1M | |
| Marketable securities, non-current | $18.1M | ||
| Operating lease right-of-use asset | $20.1M | $23.2M | |
| Other assets | $3.0M | $7.9M | |
| Total assets | $397.1M | $240.5M | |
| Accounts payable | $1.8M | $1.9M | |
| Accrued expenses and other current liabilities | $16.0M | $14.1M | |
| Operating lease liabilities, current | $4.8M | $4.6M | |
| Total current liabilities | $22.6M | $20.7M | |
| Operating lease liabilities, net of current portion | $18.5M | $22.0M | |
| Other liabilities, non-current | $1.1M | $969.0K | |
| Total liabilities | $42.2M | $43.6M | |
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of December 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | $0 | $508.1M | |
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 49,335,551 and 2,446,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively; 10,372 shares subject to repurchase as of December 31, 2025 and 2024 | $49.0K | $2.0K | |
| Additional paid-in-capital | $844.4M | $47.2M | |
| Accumulated other comprehensive income | $110.0K | ||
| Accumulated deficit | -$489.5M | -$358.4M | |
| Total stockholders' equity (deficit) | $355.0M | -$311.2M | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $397.1M | $240.5M | |
| Preferred stock, par or stated value per share | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | 410.0M shares |
| Common stock, shares, issued | 49.3M shares | 2.4M shares | |
| Common stock, shares, outstanding | 49.3M shares | 2.4M shares | |
| Common stock, shares, subject to repurchase | 10.4K shares | 10.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$131.1M | $52.2M |
| Depreciation expense | $2.4M | $3.3M |
| Stock-based compensation expense | $16.4M | $9.6M |
| Non-cash lease expense | $3.1M | $2.9M |
| Accretion of discounts on marketable securities, net | -$505.0K | |
| Change in fair value of convertible promissory notes | $8.8M | |
| Other items, net | $21.0K | $577.0K |
| Prepaid expenses and other current assets | -$2.9M | $93.0K |
| Other assets | $537.0K | -$2.3M |
| Accounts payable | -$27.0K | -$204.0K |
| Accrued expenses and other liabilities | $3.5M | $3.8M |
| Operating lease liabilities | -$3.3M | -$2.9M |
| Net cash (used in) provided by operating activities | -$111.9M | $76.0M |
| Purchases of marketable securities | -$187.7M | |
| Maturities of marketable securities | $17.5M | |
| Purchases of property and equipment | -$794.0K | -$1.1M |
| Net cash used in investing activities | -$171.0M | -$1.1M |
| Proceeds from initial public offering, net of offering costs paid | $127.8M | |
| Proceeds from private placement, net of offering costs paid | $141.3M | |
| Proceeds from exercise of stock option awards, net of repurchases | $5.6M | $733.0K |
| Proceeds from issuance of common stock under the 2025 Employee Stock Purchase Plan | $1.3M | |
| Payment of success fee derivative | -$500.0K | |
| Proceeds from exercise of pre-funded warrants | $1.0K | |
| Payment of deferred offering costs | -$3.2M | |
| Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs | $70.8M | |
| Proceeds from issuance of convertible promissory notes, net of issuance costs | $24.5M | |
| Net cash provided by financing activities | $275.3M | $92.8M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$7.6M | $167.7M |
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $5.0K | $59.0K |
| Vesting of restricted stock and stock options subject to repurchase | $23.0K | |
| Offering costs recorded in accounts payable and accrued expenses | $11.0K | $1.1M |
| Settlement of convertible promissory notes by conversion to Series D-1 redeemable convertible preferred stock | $53.4M | |
| Deemed dividend for anti-dilution adjustments to Series B and Series C redeemable convertible preferred stock upon issuance of Series D redeemable convertible preferred stock | $15.0M | |
| Income taxes paid | $1.2M |
No quarter-by-quarter statement was filed.
Corporate structure
Maze Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Maze Therapeutics, Inc.
- Paradigm Biocapital Advisors LP Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Aug 14, 2026 (2 filings since Apr 1, 2026)
- BlackRock Filed SCHEDULE 13G on Maze Therapeutics, Inc., latest Jul 29, 2026
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest May 15, 2026 (4 filings since May 14, 2025)
- Frazier Life Sciences Public Fund, L.P. Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Feb 13, 2026 (5 filings since Feb 10, 2025)
- Third Rock Ventures IV, L.P. Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Feb 13, 2026 (2 filings since May 9, 2025)
- GV 2019, L.P. Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Feb 6, 2026 (2 filings since May 9, 2025)
- Foresite Capital Fund IV, L.P. Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Nov 14, 2025 (3 filings since Feb 7, 2025)
- Matrix Capital Management Company, LP Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Nov 13, 2025 (2 filings since May 14, 2025)
- Deep Track Capital, LP Filed SCHEDULE 13G/A on Maze Therapeutics, Inc., latest Aug 14, 2025 (2 filings since Feb 7, 2025)
- ARCH Venture Fund X, L.P. Filed SCHEDULE 13G on Maze Therapeutics, Inc., latest May 15, 2025
- Maze Therapeutics, Inc. South San Francisco, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Maze Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $24.3M2 Dec 31, 2025 | $23.5M2 Dec 31, 2024 | +3.1% |
| Accumulated depreciation | $19.2M2 Dec 31, 2025 | $16.9M2 Dec 31, 2024 | +13.9% |
| Property and equipment, net | $5.0M2 Dec 31, 2025 | $6.7M2 Dec 31, 2024 | −24.4% |
| Operating-lease assets (leased space) | $20.1M2 Dec 31, 2025 | $23.2M2 Dec 31, 2024 | −13.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $189.2M2 Dec 31, 2025 | $196.8M2 Dec 31, 2024 | −3.8% |
| Marketable securities, current | $152.7M2 Dec 31, 2025 | ||
| Marketable securities, non-current | $18.1M2 Dec 31, 2025 | ||
| Debt securities available for sale | $170.8M2 Dec 31, 2025 |
Properties, in its own words
Our corporate headquarters is located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California, where we lease and occupy approximately 67,000 square feet of office and laboratory space. Our lease, entered into on September 27, 2019 expires in November 2030 with an option to extend the lease term for an additional period of eight years.
We believe our existing facility is sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.
Item 2 of the 10-K filed Mar 25, 2026.4
Leadership
Who has led Maze Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerJason Coloma V. Jan 30, 2025 to now7
- PresidentHarold Bernstein Jan 30, 2025 to now8
- Chief financial officerMisbah Tahir Sep 2, 2025 to now9
Board members and other officers (19)
- SVP, FinanceAmy Bachrodt Jan 30, 2025 to now10
- CSBOAtul Dandekar Jan 30, 2025 to now11
- GC and Corp. SecretaryPhillips Courtney Jan 30, 2025 to now12
- Board memberNeil Kumar Mar 31, 2026 to now13
- Board memberPaula Johnson Aug 17, 2026 to now14
- Board memberSophie Kornowski Aug 17, 2026 to now15
- Board memberAlan Colowick Jan 30, 2025 to Jan 30, 202516
- Board memberCatherine A. Sohn Jan 30, 2025 to now17
- Board memberCharles J. Homcy Jan 30, 2025 to now18
- Board memberDaniel K. Spiegelman Jan 30, 2025 to now19
- Board memberJames Brush Jan 30, 2025 to Jan 30, 202520
- Board memberJason Coloma V. Jan 30, 2025 to now7
- Board memberJeffrey K. Tong Jan 30, 2025 to Jan 30, 202521
- Board memberJonathan E. Lim Jan 30, 2025 to now22
- Board memberNancy C. Andrews Jan 30, 2025 to now23
- Board memberNeil Exter Jan 30, 2025 to now24
- Board memberRichard H. Scheller Jan 30, 2025 to now25
- Board memberSekar Kathiresan Jan 30, 2025 to now26
- Board memberHerve Hoppenot Oct 7, 2025 to now27
Timeline
- Aug 17, 20268-K Executive or director change; Regulation FD disclosure28
- Aug 11, 20268-K Results of operations29
- Jun 10, 20268-K Shareholder vote30
- May 22, 20268-K Executive or director change31
- May 12, 20268-K Results of operations32
- Apr 22, 20268-K Other events33
- Mar 25, 20268-K Results of operations; Executive or director change; Regulation FD disclosure34
- Feb 4, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation35
- Nov 6, 20258-K Results of operations36
- Oct 6, 20258-K Executive or director change37
- Sep 11, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure38
- Sep 2, 20258-K Executive or director change39
- Jan 30, 2025New chief executive Jason Coloma V. becomes CEO7
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.66) a share, on Nov 6, 2025.40
When it reported results
- Aug 11, 2026Reported quarterly or annual results29
- May 12, 2026Reported quarterly or annual results32
- Mar 25, 2026Reported quarterly or annual results34
- Nov 6, 2025Reported quarterly or annual results36
- Aug 12, 2025Reported quarterly or annual results41
- May 14, 2025Reported quarterly or annual results42
- Mar 31, 2025Reported quarterly or annual results43
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
217 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 15 major events, 106 insider forms, 24 large holders, 65 other. The latest 20:
- Oct 2, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 1, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 8, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
51 open-market trades by officers, directors and large owners since October 2021: 0 buys and 51 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 9,705 | $26.22 | $254.5K | Form 4 |
| Sep 3, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 5,189 | $26.01 | $135.0K | Form 4 |
| Sep 3, 2026 | Dandekar AtulCSBO | Sale | 3,243 | $26.01 | $84.3K | Form 4 |
| Sep 3, 2026 | Courtney PhillipsGC and Corp. Secretary | Sale | 2,012 | $26.01 | $52.3K | Form 4 |
| Sep 3, 2026 | Coloma Jason VChief Executive Officer | Sale | 11,411 | $26.01 | $296.8K | Form 4 |
| Sep 2, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 5,106 | $26.47 | $135.2K | Form 4 |
| Sep 2, 2026 | Dandekar AtulCSBO | Sale | 3,191 | $26.47 | $84.5K | Form 4 |
| Sep 2, 2026 | Courtney PhillipsGC and Corp. Secretary | Sale | 1,981 | $26.47 | $52.4K | Form 4 |
| Sep 2, 2026 | Coloma Jason VChief Executive Officer | Sale | 11,227 | $26.47 | $297.2K | Form 4 |
| Sep 1, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 16,141 | $26.36 | $425.5K | Form 4 |
| Sep 1, 2026 | Coloma Jason VChief Executive Officer | Sale | 34,501 | $26.29 | $907.1K | Form 4 |
| Aug 28, 2026 | Dandekar AtulCSBO | Sale | 7,500 | $27.58 | $206.8K | Form 4 |
| Aug 13, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 16,142 | $27.61 | $445.7K | Form 4 |
| Aug 3, 2026 | Coloma Jason VChief Executive Officer | Sale | 34,501 | $26.73 | $922.2K | Form 4 |
| Jul 29, 2026 | Dandekar AtulCSBO | Sale | 7,500 | $27.34 | $205.1K | Form 4 |
| Jul 1, 2026 | Bernstein HaroldPresident, R&D & CMO | Sale | 14,609 | $29.91 | $436.9K | Form 4 |
| Jul 1, 2026 | Coloma Jason VChief Executive Officer | Sale | 34,501 | $29.97 | $1.0M | Form 4 |
| Jun 29, 2026 | Dandekar AtulCSBO | Sale | 7,500 | $28.02 | $210.2K | Form 4 |
| Jun 23, 2026 | Coloma Jason VChief Executive Officer | Sale | 23,865 | $26.05 | $621.7K | Form 4 |
| Jun 22, 2026 | Coloma Jason VChief Executive Officer | Sale | 3,993 | $26.00 | $103.8K | Form 4 |
All 51 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Paradigm Biocapital Advisors LPSCHEDULE 13G/A, 2 filings Apr 1, 2026 to Aug 14, 202644
- BlackRockSCHEDULE 13G, 1 filing Jul 29, 202645
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 4 filings May 14, 2025 to May 15, 202646
- Frazier Life Sciences Public Fund, L.P.SCHEDULE 13G/A, 5 filings Feb 10, 2025 to Feb 13, 202647
- Third Rock Ventures IV, L.P.SCHEDULE 13G/A, 2 filings May 9, 2025 to Feb 13, 202648
- GV 2019, L.P.SCHEDULE 13G/A, 2 filings May 9, 2025 to Feb 6, 202649
- Foresite Capital Fund IV, L.P.SCHEDULE 13G/A, 3 filings Feb 7, 2025 to Nov 14, 202550
- Matrix Capital Management Company, LPSCHEDULE 13G/A, 2 filings May 14, 2025 to Nov 13, 202551
- Deep Track Capital, LPSCHEDULE 13G/A, 2 filings Feb 7, 2025 to Aug 14, 202552
- ARCH Venture Fund X, L.P.SCHEDULE 13G, 1 filing May 15, 202553
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Misbah Tahir | 51 | $3.7M | $4.0M54 |
| 2025 | Jason ColomaPh.D. | $629.2K | $3.5M54 | |
| 2025 | Harold BernsteinM.D., Ph.D. | $548.3K | $1.8M54 | |
| 2024 | Chief Executive Officer | $280.5K | $5.8M54 | |
| 2024 | PresidentResearch and Development and Chief Medical Officer | $526.7K | $2.4M54 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | $150.2M | 3.3% | +465,641 |
| Trv Gp Iv, LLC | 4,473,958 | $133.5M | 52.6% | No change |
| ARCH Venture Management, LLC | 4,120,053 | $123.0M | 11.2% | No change |
| Deep Track Capital, LP | 3,732,569 | $111.4M | 1.6% | +255,007 |
| BlackRock, Inc. | 3,502,841 | $104.5M | 0.0% | +932,416 |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 0.0% | New |
| Logos Global Management LP | 1,935,000 | $57.7M | 2.5% | +700,000 |
| Vanguard Capital Management LLC | 1,778,222 | $53.1M | 0.0% | +342,566 |
| a16z Capital Management, L.L.C. | 1,702,225 | $50.8M | 0.4% | No change |
| Venrock Adviser, LLC | 1,602,034 | $47.8M | 1.4% | No change |
| Alphabet Inc. | 1,388,583 | $41.4M | 0.0% | No change |
| Braidwell LP | 1,140,040 | $34.0M | 1.3% | New |
| Farallon Capital Management, L.l.c. | 1,107,814 | $33.1M | 0.2% | +734,814 |
| Fmr LLC | 1,056,959 | $31.5M | 0.0% | +192,745 |
| General Catalyst Group Management, LLC | 1,035,910 | $30.9M | 16.4% | No change |
| State Street Corp | 997,533 | $29.8M | 0.0% | +360,811 |
| Driehaus Capital Management LLC | 954,886 | $28.5M | 0.2% | +318,724 |
| Trv Gp V, LLC | 950,800 | $28.4M | 5.7% | No change |
| Jpmorgan Chase & Co | 964,011 | $28.0M | 0.0% | +905,565 |
| Marshall Wace, Llp | 914,572 | $27.3M | 0.0% | +603,933 |
| Geode Capital Management, LLC | 858,054 | $25.6M | 0.0% | +258,087 |
| Citadel Advisors LLC | 852,676 | $25.4M | 0.0% | +76,962 |
| Casdin Capital, LLC | 843,857 | $25.2M | 1.3% | +85,000 |
| ArrowMark Colorado Holdings LLC | 767,383 | $22.9M | 1.0% | No change |
| Woodline Partners LP | 736,216 | $22.0M | 0.1% | +85,987 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Maze Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMaze Therapeutics, Inc.1
- CIK0001842295
- Employer ID (EIN)82-26350184
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address171 Oyster Point Boulevard, Suite 300, South San Francisco, CA 940801
- Phone65085050701
- Shares outstanding55,549,168 as of Aug 5, 20266
- Public float$443.9M as of Jun 30, 20254
- AuditorErnst & Young LLP, San Mateo, California PCAOB ID 42; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceJun 21, 20241
- Filings217 in all: 4 (83), 144 (24), 3 (23), 8-K (15), SCHEDULE 13G/A (13), SCHEDULE 13G (11), CORRESP (6), UPLOAD (6)1
All 29 form types
10-Q (5), DRS/A (4), DRSLTR (3), 10-K (2), EFFECT (2), S-1 (2), S-1/A (2), S-8 (2), SEC STAFF LETTER (2), 424B3 (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), DEF 14A (1), DEFA14A (1), DRS (1), POS AM (1), S-1MEF (1), S-3ASR (1)
- Latest filingsAnnual report (10-K) Mar 25, 2026
Quarterly report (10-Q) Aug 11, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 17, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock - par value $0.001 per share | MAZE | Nasdaq |
From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Maze Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 25, 2026: 72 risks under these headings, as written.4
- Risks related to our limited operating history, financial position and need for capital
- We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability. Since our inception, we have incurred significant operating losses and have not generated any product revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.
- We will require substantial additional capital to finance our operations and achieve our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization efforts or other operations.
- Raising additional capital may cause dilution to our stockholders, cause the price of our common stock to decline, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates.
- Our loan and security agreement provides our lender with a first priority lien against substantially all of our assets, except for intellectual property, and contains restrictive and financial covenants that may limit our operating flexibility.
- Risks related to discovery and development of our therapeutic candidates
- We are early in our development efforts and highly dependent on the success of our lead programs. If we are unable to commercialize our therapeutic candidates or experience significant delays in doing so, our business will be materially harmed.
- Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our therapeutic candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates on a timely basis or at all.
- Results of preclinical studies or early-stage clinical trials of any therapeutic candidates may not be predictive of the results of future preclinical studies or clinical trials.
- If we encounter delays or difficulties enrolling patients in our clinical trials and/or retaining patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- Our therapeutic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences.
- We may not be successful in applying our Compass platform to identify targets with therapeutic potential or to discover and develop safe, effective or commercially viable therapeutic candidates.
The other 62 risks
- Certain of the diseases we, or which our partners, seek to treat have low prevalence and/or have available therapies, and it may be difficult for us or our partners to identify patients with these diseases or face competition in the recruitment of these limited groups of patients, which may lead to difficulties in enrolling clinical trials.
- We may experience delays in commencing and completing, or ultimately be unable to complete, the development and/or commercialization of our therapeutic candidates.
- We may expend our limited resources to pursue a particular therapeutic candidate or indication and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- If ethical and other concerns surrounding the use of genetic information become widespread, there may be limitations on our ability to access genetic information for our Compass platform.
- Interim, topline and preliminary data from preclinical studies and clinical trials that we or our partners announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- If we do not achieve our projected development goals in the time frames we announce or expect, the development of our therapeutic candidates may be delayed and, as a result, our stock price may decline.
- Risks related to our reliance on third parties
- Our Compass platform relies on access to high quality data repositories with paired genetic and clinical data and loss of such access, or the inability to use such data, could have a material adverse effect on our business, financial condition, results of operations and prospects.
- We have entered, and may in the future enter, into strategic collaborations, transactions and licensing partnerships for research, development or commercialization of our programs, including our first therapeutic candidate MZE001, and we may not be able to realize the full value of these partnerships or our partnered programs.
- We face risks associated with new companies we may create, such as joint ventures and spin-outs.
- We rely on third parties to conduct current and future clinical trials, and those third parties may not perform satisfactorily or at all, including failing to meet deadlines for completing such trials, failing to satisfy legal or regulatory requirements or terminating the relationship.
- We rely on third parties to manufacture our clinical product supplies and therapeutic candidates and we may not be able to obtain adequate supplies at a reasonable cost or in a timely manner.
- We or some of our suppliers may experience disruption to our or their respective supply chain due to the effects of macroeconomic conditions, which could delay, prevent or impair our development or commercialization efforts.
- Our reliance on third parties requires us to share certain of our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed.
- Risks related to government regulation
- The FDA regulatory approval process is lengthy and time-consuming.
- We, as a company, have limited experience in submitting INDs in the United States and we do not have experience in obtaining regulatory approval to initiate clinical trials in any other jurisdiction. Nor do we have experience in manufacturing or in quality assurance in order to market our therapeutic candidates in the United States or in any other jurisdiction.
- Our failure to obtain marketing approval in foreign jurisdictions would prevent our therapeutic candidates from being marketed abroad, and any approval we are granted for our therapeutic candidates in the United States would not assure approval of therapeutic candidates in foreign jurisdictions.
- If we decide to pursue a fast track designation by the FDA, it may not lead to a faster development or regulatory review or approval process.
- If we decide to pursue accelerated approval for any of our therapeutic candidates, it may not lead to a faster regulatory review or approval process and does not increase the likelihood that our therapeutic candidates will receive marketing approval.
- If generic versions of our small molecule therapeutic candidates are approved, our revenue and results of operations would be adversely affected.
- Our current and future relationships with customers and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to significant penalties, including criminal, civil, and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our therapeutic candidates and may affect pricing and third-party payment for our therapeutic candidates and decrease the prices we may obtain.
- Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
- Even if we are able to commercialize a drug candidate, coverage and adequate reimbursement may not be available or such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
- Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain therapeutic candidates outside of the United States and require us to develop and implement costly compliance programs.
- If we, or any third-party contractors we engage, fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
- We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
- We are, and may in the future be, subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.
- Risks related to commercialization of our therapeutic candidates
- We face significant competition in an environment of rapid technological change and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our therapeutic candidates.
- Even if our Compass platform is effective as a research tool, we may be unable to develop or commercialize new drugs, therapies or other products based on discoveries from our Compass platform.
- We, or the third parties we rely on, may be unable to develop the diagnostic tests or clinical assays to successfully advance our therapeutic candidates through clinical trials or commercialization.
- We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
- Even if any of our therapeutic candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any therapeutic candidates that we may develop alone or with partners.
- Our estimated market opportunities for our therapeutic candidates are subject to numerous uncertainties and may prove to be inaccurate. If we have overestimated the size of our market opportunities, our future growth may be limited.
- Risks related to our business operations
- Our future success depends on our ability to retain key employees, to engage advisors and consultants and to attract, retain and motivate qualified personnel.
- We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
- Our current or future employees, clinical trial investigators, CROs, CMOs, consultants, vendors and partners may engage in misconduct or other improper activities, including non-compliance with regulatory requirements, violations of regulatory standards, and insider trading.
- Our business is dependent on the integrity of information technology systems and failure of such systems could disrupt our business.
- We utilize third-party open source software, and any failure to comply with the terms of one or more of these open source software licenses could adversely affect our business, subject us to litigation, or create potential liability.
- The use of new and evolving technologies, such as AI in our operations may require us to expend material resources and may present risks and challenges that can impact our business, including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or otherwise adversely affect our business.
- Our ability to use our net operating loss and certain other tax attributes may be limited.
- We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
- Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations and prospects, which could lead to a decline in our stock price.
- Risks related to intellectual property
- Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- We may not be able to protect our intellectual property rights throughout the world.
- If we are sued for infringing, misappropriating or otherwise violating intellectual property or proprietary rights of third parties, such litigation or disputes could be costly and time-consuming and could prevent or delay us from developing or commercializing our therapeutic candidates.
- Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
- We may be subject to claims by third parties asserting that we, or our employees or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and any future patent protection could be reduced or eliminated for noncompliance with these requirements.
- If we are unable to protect the confidentiality of our trade secrets, the value of our therapeutic candidates and technologies could be materially adversely affected and our business would be harmed.
- If we fail to comply with our obligations in any agreements under which we may license intellectual property rights to or from third parties or otherwise experience disruptions to our business relationships with our current partners or any future licensors, we could lose license rights that are important to our business.
- If we cannot acquire or license rights to use technologies on reasonable terms or at all, we may not be able to commercialize our current or any future products or technologies.
- If we do not obtain patent term extension and data exclusivity for any therapeutic candidates we may develop, our business may be materially harmed.
- We may become involved in lawsuits to protect or enforce any patents we may own or in-license in the future, which could be expensive, time consuming and unsuccessful and any patents we may own or in-license in the future covering our therapeutic candidates could be found invalid or unenforceable if challenged in courts or patents offices.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Intellectual property rights do not necessarily address all potential commercial or competitive threats.
- Risks related to our common stock
- The market price of our common stock may be highly volatile, and you could lose all or part of your investment.
- If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our company, our common stock price and trading volume could decline.
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
- Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.
- The exclusive forum provisions in our organizational documents may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.
Legal proceedings
From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources, negative publicity and reputational harm.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARHarold Bernstein, President
- 9
- 10SEC EDGARAmy Bachrodt, SVP, Finance
- 11SEC EDGARAtul Dandekar, CSBO
- 12
- 13SEC EDGARNeil Kumar, Board member
- 14SEC EDGARPaula Johnson, Board member
- 15SEC EDGARSophie Kornowski, Board member
- 16SEC EDGARAlan Colowick, Board member
- 17SEC EDGARCatherine A. Sohn, Board member
- 18SEC EDGARCharles J. Homcy, Board member
- 19SEC EDGARDaniel K. Spiegelman, Board member
- 20SEC EDGARJames Brush, Board member
- 21SEC EDGARJeffrey K. Tong, Board member
- 22SEC EDGARJonathan E. Lim, Board member
- 23SEC EDGARNancy C. Andrews, Board member
- 24SEC EDGARNeil Exter, Board member
- 25SEC EDGARRichard H. Scheller, Board member
- 26SEC EDGARSekar Kathiresan, Board member
- 27SEC EDGARHerve Hoppenot, Board member
- 28
- 29SEC EDGARResults of operations
- 30SEC EDGARShareholder vote
- 31SEC EDGARExecutive or director change
- 32SEC EDGARResults of operations
- 33SEC EDGAROther events
- 34
- 35
- 36SEC EDGARResults of operations
- 37SEC EDGARExecutive or director change
- 38
- 39SEC EDGARExecutive or director change
- 40NasdaqNasdaq calendar
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54